Department of Health and Human Services (HHS)
It is therefore the synergistic actions of GLP-1 in the gut and brain, acting on both central and peripheral receptors that seem responsible for the effects of the hormone on satiety. How this mechanism promotes weight loss : patients eat less and feel more satisfied
#2 Developing new portion-controlled, nutrient-rich, high-protein snacks or other products tailored to users of these drugs and those trying to wean themselves off said drugs without regaining all the weight, in part to counteract the muscle loss associated with taking these medications
Pallard FV, Markovic J, Garca JL, Via J
health insurance landscape creates both the opportunity and the constraint: commercial insurance covering GLP-1 for diabetes generates large, well-reimbursed prescription volumes, but coverage for obesity indications varies widely, with Medicare explicitly prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act passes a legislative gap that excludes tens of millions of Medicare beneficiaries from covered GLP-1 obesity access